Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients
Phase 2
Completed
- Conditions
- Open-angle GlaucomaOcular Hypertension
- Interventions
- Drug: AL-12182 0.003% Ophthalmic SolutionOther: AL-12182 Ophthalmic Solution VehicleDrug: AL-12182 0.01% Ophthalmic SolutionDrug: AL-12182 0.03% Ophthalmic Solution
- Registration Number
- NCT00069706
- Lead Sponsor
- Alcon Research
- Brief Summary
The purpose of this study is to determine the safety and IOP-lowering ability of a glaucoma therapy in patients with open-angle glaucoma or ocular hypertension.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 118
Inclusion Criteria
- 18 years or older.
- Diagnosis of open-angle glaucoma or ocular hypertension.
- LogMAR visual acuity not worse than 0.6.
- Other protocol-defined inclusion criteria may apply.
Exclusion Criteria
- Clinically relevant ophthalmic or systemic conditions.
- Other protocol-defined exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description AL-12182 0.003% AL-12182 0.003% Ophthalmic Solution One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days AL-12182 Solution Vehicle AL-12182 Ophthalmic Solution Vehicle One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days Latanoprost Latanoprost 0.005% Ophthalmic Solution One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days AL-12182 0.01% AL-12182 0.01% Ophthalmic Solution One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days AL-12182 0.03% AL-12182 0.03% Ophthalmic Solution One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
- Primary Outcome Measures
Name Time Method Mean Intraocular Pressure (IOP)
- Secondary Outcome Measures
Name Time Method